Release Details

- Poster Presentation to Reveal First Clinical Data for IMO-8400 as Potential Treatment for Waldenström’s Macroglobulinemia -

CAMBRIDGE, Mass. and EXTON, Pa., Nov. 05, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that new data from the Phase 1/2 clinical trial for IMO-8400, a TLR 7,8 and 9 antagonist, being evaluated for the treatment of relapsed, refractory patients suffering from Waldenström’s Macroglobulinemia, will be presented at the 2015 American Society of Hematology (ASH) Annual Meeting in Orlando, FL, December 5-8, 2015.

The open-label, dose-ranging clinical trial included three dose-escalating cohorts on IMO-8400 and enrolled 19 patients, who were relapsed or refractory to prior therapies.  Data from these 19 patients will be presented at the ASH Meeting.

“The presentation of the clinical safety and efficacy data from our IMO-8400 study in Waldenström’s Macroglobulinemia is a positive step forward for our company, for our clinical aspirations in cancer care and for the role of Toll-Like Receptors as a therapeutic option for patients suffering from B-cell Lymphomas,” stated Vincent Milano, Idera’s Chief Executive Officer.  “We look forward to presenting the data next month at the ASH conference and beginning to elucidate the path forward for IMO-8400 beyond this first clinical study.”

Poster Presentation

Date: Saturday, December 5, 2015, Presentation Time: 5:30 PM ET – 7:30 PM ET
Session Title:  624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster I
Publication Number:  1540
Presentation Title:  Preliminary Results from a Phase 1/2 Open-Label, Dose-Escalation Clinical Trial of IMO-8400 in Patients with Relapsed or Refractory Waldenström’s Macrogloblulinemia
Location:  Orange County Convention Center, Hall A

About Idera Pharmaceuticals            

Idera Pharmaceuticals is a clinical-stage patient focused biopharmaceutical company developing novel therapeutic approaches for the treatment of cancer and rare diseases. Idera’s proprietary technology involves creating novel nucleic acid therapeutics. Idera’s immunotherapy approach is based on the modulation of Toll-like receptors (TLRs).  In addition to its TLR modulation programs, Idera is developing third generation antisense technology that it has created to inhibit the production of disease-associated proteins by targeting RNA. To learn more about Idera, visit www.iderapharma.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements about potential treatments for Waldenström’s Macroglobulinemia. Such statements may be identified by words such as "believe," "expect," "may," "plan," "potential," "will" and similar expressions, and are based on the company’s current beliefs and expectations. Development of drug therapies involves a high degree of risk, and only a small percentage of research and development programs undertaken may result in the commercialization of a product. Positive preclinical data does not ensure that later stage clinical trials will be successful. For more detailed information on the risks and uncertainties associated with Idera’s development activities, please review the Risk Factors section of Idera's most recent annual or quarterly report filed with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and the company assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor and Media Contact
Robert Doody
Vice President, Investor Relations and Corporate Communications
484‐639‐7235
rdoody@iderapharma.com